Addressing Methamphetamine Abuse at the Pharmacy Counter

Shilpa Amara, PharmD
Published Online: Monday, September 16, 2013
Follow Pharmacy_Times:

This activity is supported by an educational grant from Acura Pharmaceuticals Inc.

Addressing Methamphetamine Abuse at the Pharmacy Counter

Shilpa Amara, PharmD
Drug Information Specialist
Barnabas Health
South Plainfield, New Jersey



Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty
Shilpa Amara, PharmD

Pharmacy Times Office of Continuing Professional Education

Planning Staff
Judy V. Lum, MPA, and Steve Lin, PharmD

Pharmacy Times Editorial Staff
Kirk McKay and David Allikas

An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.



Educational Objectives
 
Upon completion of the educational activity, the participant should be able to:
  1. Discuss the origins of methamphetamine abuse and its health and economic toll.
  2. Examine the current status of methamphetamine abuse following implementation of legal restrictions on purchasing of implicated OTC drugs.
  3. Identify further efforts taken to minimize use of OTC drugs for manufacture of methamphetamine.
  4. Identify pharmacy implications associated with use of OTC products in methamphetamine production.
Target audience:   Pharmacists
Type of activity:   Knowledge
Release date:   September 13, 2013
Expiration date:   September 13, 2015
Estimated time to complete activity:   2 hours
Fee:   Free

Click here to view this activity.

Related Articles
Twenty-two pharmacists and doctors were arrested in the Drug Enforcement Administration's “Operation Pilluted” aimed at curbing prescription drug abuse.
Deaths related to oxycodone overdose dropped 25% in Florida after the state adopted a Prescription Drug Monitoring Program to track controlled substance dispensing.
While health care providers generally favor pre-exposure prophylaxis (PrEP) for patients at high risk of acquiring human immunodeficiency virus (HIV), many hesitate to actually prescribe it.
The FDA has outlined the type of studies opioids need to complete to win approval for abuse-deterrence.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$